440,000 Shares in Xenon Pharmaceuticals Inc. $XENE Purchased by Trails Edge Capital Partners LP

Posted by Brenda Bartman on Aug 26th, 2026

Trails Edge Capital Partners LP acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 440,000 shares of the biopharmaceutical company’s stock, valued at approximately $26,558,400. Xenon Pharmaceuticals makes up about 0.0% of Trails Edge Capital Partners LP’s investment portfolio, making the stock its 8th largest holding. Trails Edge Capital Partners LP owned about 0.46% of Xenon Pharmaceuticals at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Goldman Sachs Group Inc. boosted its stake in shares of Xenon Pharmaceuticals by 7.9% during the first quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock valued at $14,854,000 after acquiring an additional 32,486 shares during the last quarter. Jump Financial LLC bought a new position in Xenon Pharmaceuticals during the second quarter worth about $532,000. Sei Investments Co. bought a new stake in Xenon Pharmaceuticals in the second quarter valued at about $711,000. The Manufacturers Life Insurance Company bought a new position in Xenon Pharmaceuticals in the second quarter valued at approximately $816,000. Finally, Alliancebernstein L.P. raised its position in shares of Xenon Pharmaceuticals by 14.2% in the second quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock valued at $47,530,000 after buying an additional 189,141 shares in the last quarter. Institutional investors and hedge funds own 95.45% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on XENE. Royal Bank Of Canada cut their price objective on shares of Xenon Pharmaceuticals from $82.00 to $81.00 and set an “outperform” rating for the company in a research report on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Monday, July 6th. Wells Fargo & Company restated an “overweight” rating and issued a $69.00 price objective on shares of Xenon Pharmaceuticals in a report on Sunday, May 10th. JPMorgan Chase & Co. boosted their price target on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a report on Wednesday, May 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $74.00 target price on shares of Xenon Pharmaceuticals in a report on Monday, August 10th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $77.13.

Get Our Latest Stock Analysis on XENE

Insiders Place Their Bets

In other news, Director Gary Patou sold 1,322 shares of the stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the sale, the director owned 24,896 shares of the company’s stock, valued at approximately $1,322,973.44. This represents a 5.04% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Steven Gannon sold 10,000 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $64.06, for a total transaction of $640,600.00. Following the transaction, the director directly owned 1,870 shares of the company’s stock, valued at $119,792.20. The trade was a 84.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 12,512 shares of company stock worth $774,088. 2.91% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Stock Performance

Shares of XENE stock traded down $1.94 during mid-day trading on Friday, hitting $59.99. The company’s stock had a trading volume of 587,871 shares, compared to its average volume of 1,251,618. Xenon Pharmaceuticals Inc. has a 52-week low of $35.60 and a 52-week high of $72.66. The business has a 50-day moving average price of $63.04 and a 200 day moving average price of $56.36. The stock has a market cap of $5.80 billion, a price-to-earnings ratio of -12.66 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE – Get Free Report) last issued its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.16) by $0.05. During the same quarter in the previous year, the firm posted ($1.07) EPS. Equities research analysts predict that Xenon Pharmaceuticals Inc. will post -4.73 EPS for the current fiscal year.

About Xenon Pharmaceuticals

(Free Report)

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.